**Relationship between the expression of cyclooxygenase 2 and MDR1/P-glycoprotein in invasive breast cancers and their prognostic significance**

Pawel Surowiak¹,²,³, Verena Materna¹, Rafal Matkowski⁴, Katarzyna Szczuraszek², Jan Kornafel⁴, Andrzej Wojnar³, Marek Pudelko³, Manfred Dietel¹, Carsten Denkert¹, Maciej Zabel²,⁵ and Hermann Lage¹

¹Institute of Pathology, Charité Campus Mitte, Berlin, Germany
²Chair and Department of Histology and Embryology, University School of Medicine, Wrocław, Poland
³Lower Silesian Centre of Oncology, Wrocław, Poland
⁴Chair and Department of Oncology, University School of Medicine, Wrocław, Poland
⁵Chair and Department of Histology and Embryology, University School of Medicine, Poznań, Poland

Corresponding author: Hermann Lage, hermann.lage@charite.de

Received: 8 Apr 2005 Revisions requested: 26 Apr 2005 Revisions received: 9 Jun 2005 Accepted: 2 Aug 2005 Published: 25 Aug 2005

**Abstract**

**Introduction** Recent reports suggest that expression of the cyclooxygenase 2 (COX-2) enzyme may up-regulate expression of MDR1/P-glycoprotein (MDR1/P-gp), an exponent of resistance to cytostatic drugs. The present study aimed at examining the relationship between the expression of COX-2 and of MDR1/P-gp in a group of breast cancer cases.

**Methods** Immunohistochemical reactions were performed using monoclonal antibodies against COX-2 and MDR1/P-gp on samples originating from 104 cases of primary invasive breast cancer.

**Results** COX-2-positive cases were shown to demonstrate higher expression of MDR1/P-gp (P < 0.0001). The studies also demonstrate that COX-2 expression was typical for cases of a higher grade (P = 0.01), a shorter overall survival time (P < 0.0001) and a shorter progression-free time (P < 0.0001). In the case of MDR1/P-gp, its higher expression characterised cases of a higher grade (P < 0.0001), with lymph node involvement (P < 0.0001), and shorter overall survival (P < 0.0001) and progression-free time (P < 0.0001).

**Conclusion** Our studies confirmed the unfavourable prognostic significance of COX-2 and MDR1/P-gp. We also document a relationship between COX-2 and MDR1/P-gp, which suggests that COX-2 inhibitors should be investigated in trials as a treatment supplementary to chemotherapy of breast cancers.

**Introduction** Breast cancer is the most common malignant tumour of females in the western world [1]. The incidence of breast cancer remains high, and its clinical courses are highly variable. It is of general importance to predict the biology of the tumour and, thus, the course of the disease in the individual patient to ensure adequate therapy and patient surveillance [2]. The principal therapeutic approach in breast cancer involves surgery. In advanced cases supplementary therapy is needed, involving chemotherapy and/or radiotherapy. Among the pharmacological means, tamoxifen used to be applied most frequently, as well as various chemotherapeutic regimes, including CMF (cyclophosphamide, methotrexate and 5-fluorouracil), anthracyclines and paclitaxel [3,4]. The main reason for therapeutic failure in cases of invasive breast cancers involves resistance to anti-estrogenic treatment and to chemotherapy [5,6]. Identification of the factors that characterise the resistant cases would permit immediate treatment of the patients with alternative therapeutic approaches. These factors could also provide potential targets for studies on novel therapeutic procedures.

COX = cyclooxygenase; coxibs = cyclooxygenase 2 inhibitors; IRS = immunoreactive score; MDR = multidrug resistance; MDR1/P-gp = MDR1/P-glycoprotein.
Cycloxygenases (COXs) comprise a group of enzymes that participate in the conversion of arachidonic acid to prostaglandins [7]. COX-2 has been characterised as an unfavourable prognostic factor in numerous solid tumours [8-10]. We demonstrated previously in breast cancer patients that expression of COX-2 represents an independent, unfavourable prognostic factor [11]. Numerous in vivo and in vitro studies indicate that COX-2 inhibitors (coxibs) enhance the efficacy of various anticancer therapy methods [7]. The effect of coxibs on the biology of the tumour has been explained by induction of apoptosis, inhibition of angiogenesis and by a decreased invasive potential of tumour cells [7]. COX-2 has also been shown to up-regulate expression of aromatase [12,13]. In cases of hormone-dependent tumours, such as breast cancer, coxibs might slow down development of the neoplastic disease by decreasing aromatase expression and, therefore, decreasing estrogen secretion. The in vitro studies have demonstrated also that COX-2 up-regulates expression of MDR1/P-glycoprotein (MDR1/P-gp) [14], the energy-dependent pump that participates in the phenomenon of multidrug resistance (MDR) [5]. MDR1/P-gp efficiently removes drugs and many commonly used pharmaceuticals from the lipid bilayer. Confirmation of the relationship between COX-2 and MDR1/P-gp in a clinical material may open novel perspectives in the therapy of tumours. Coxibs could be employed as a chemotherapy-supporting treatment, aimed at the inhibition or prevention of the development of the MDR phenomenon.

The present study aimed to examine the relationship between the expression of COX-2 and of MDR1/P-gp in primary invasive breast cancers as well as the definition of their prognostic and predictive values.

**Materials and methods**

**Patients**

Immunohistochemical analysis was performed retrospectively on tissue samples that were taken for routine diagnostic purposes. The cases were selected based on availability of tissue and were not stratified for known preoperative or pathological prognostic factors. The study was approved by an Institutional Review Board (University School of Medicine, Wroclaw, Poland) and the patients gave their informed consent before their inclusion into the study. A total of 104 patients with primary invasive breast cancer who were diagnosed in the years 1993 to 1994 in the Lower Silesian Centre of Oncology in Wroclaw, Poland, qualified for the studies. All the patients were subjected to mastectomy and, subsequently treated with radiotherapy and/or chemotherapy and/or hormonotherapy (Table 1). Compliance was monitored by the doctors in charge. The patients were monitored by periodic medical check-ups and ultrasonographic and radiological examinations. During the follow-up period, 23 patients (22%) had recurrent disease and 25 patients (24%) died of the disease. The mean (median) progression-free survival time was 76 months (range 8 to 103 months), while the mean (median) overall survival time was 81 months (range 8 to 103 months).

**Table 1**

| Characteristics    | No. (%) |
|--------------------|---------|
| All patients       | 104 (100) |
| Age (years; mean 56.2) |         |
| ≤ 50               | 33 (32)  |
| 51–60              | 29 (28)  |
| >60                | 42 (40)  |
| Menopause          |         |
| Premenopausal      | 30 (29)  |
| Postmenopausal     | 74 (71)  |
| Grade              |         |
| 2                  | 71 (68)  |
| 3                  | 33 (32)  |
| pTb                |         |
| 1                  | 17 (16)  |
| 2                  | 86 (83)  |
| 4                  | 1 (1)    |
| pNb                |         |
| 0                  | 29 (28)  |
| 1                  | 75 (72)  |
| pMb                |         |
| 0                  | 104 (100) |
| Stageb             |         |
| I                  | 3 (3)    |
| IIa                | 40 (38)  |
| Iib                | 60 (58)  |
| IIIb               | 1 (1)    |
| Histology          |         |
| Ductal             | 103 (99) |
| Scirrhous          | 1 (1)    |
| Therapya           |         |
| Tamoxifen          | 70 (67)  |
| Radiotherapy       | 51 (49)  |
| Cyclophosphamide/Methotrexate/5-Fluorouracil | 28 (27) |
| Cyclophosphamide/Adriamycin/5-Fluorouracil | 1 (1)  |
| Cyclophosphamide/Adriamycin | 1 (1) |
| Progesterone       | 1 (1)    |
| Letrozol           | 1 (1)    |

*aSome patients received more than one special treatment.

*bAccording to [15]
Fragments sampled from studied tumours were fixed in 10% buffered formaline and embedded in paraffin. In every case, hematoxylin and eosin stained preparations were subjected to histopathological evaluation by two pathologists. The stage of the tumours was assessed according to the TNM classification system [15]. Tumour grade was estimated according to Bloom-Richardson and the modification of Elston and Ellis [16] (Table 1).

Immunohistochemistry

Freshly cut sections (4 µm) of the formalin-fixed, paraffin embedded tissue were mounted on Superfrost slides (Menzel Gläser, Braunschweig, Germany), dewaxed with xylene, and gradually hydrated. Activity of endogenous peroxidase was blocked by 5 minute exposure to 3% H₂O₂. All the studied sections were boiled in Antigen Retrieval Solution (DakoCyto- mation, Glostrup, Denmark), in the case of COX-2 for 10 minutes and in the case of MDR1/P-gp for 15 minutes. Immunohistochemical reactions were performed using monoclonal mouse antibodies against COX-2 (Cayman Chemical Company, Ann Arbor, MI, USA) at a dilution of 1:2000, monoclonal mouse antibodies (clone C219) against MDR1/P-gp (Alexis Biochemicals, Grünberg, Germany) at a dilution of 1:200.

| Percentage of positive cells | Points | Intensity of reaction | Points |
|-----------------------------|--------|-----------------------|--------|
| No positive cells           | 0      | No reaction           | 0      |
| <10%                        | 1      | Weak reaction         | 1      |
| 10–50%                      | 2      | Moderate reaction     | 2      |
| 51–80%                      | 3      | Intense reaction      | 3      |
| >80%                        | 4      |                       |        |

Table 2

**Evaluation criteria of MDR1/P-gp expression using the immunoreactive score [17]**

MDR1/P-gp, MDR1/P-glycoprotein.

**Figure 1**

Immunohistochemical localization of cyclooxygenase-2 (red). The inset shows the control reaction with blocking peptide under the same conditions (hematoxylin, ×400).

**Figure 2**

(a) With antibody C219 in breast cancer (showing cytoplasmic and membrane localizations in cancer cells) and healthy human liver (inset) (hematoxylin, ×400). (b) With antibody JSB-1 in breast cancer (showing cytoplasmic and membrane localizations in cancer cells) and healthy human liver (inset) (hematoxylin, ×400).
Breast Cancer Research  Vol 7 No 5  Surowiak et al.

1:100 and monoclonal mouse antibodies (clone JSB-1) against MDR1/P-gp (Roche Diagnostics, Mannheim, Germany) at a dilution of 1:100. The antibodies were diluted in Antibody Diluent with background reducing component (DakoCytomation). Tested sections were incubated with antibodies for 1 h at room temperature. Subsequent incubations involved biotinylated antibodies (15 minutes, room temperature) and streptavidin-biotinylated peroxidase complex (15 minutes, room temperature) using a LSAB+ HRP system DakoCytomation). NovaRed (Vector Laboratories, Peterborough, UK) was used as a chromogen (10 minutes, room temperature). All the sections were counterstained with Meyer’s hematoxylin.

Evaluation of reaction intensity
The intensity of immunohistochemical reactions with COX-2 was appraised using a simplified scale. A case was diagnosed as COX-2 positive (1) when expression was observed in all tumour cells or in numerous cell clumps, or as COX-2 negative (0) when no reaction was noted or the reaction was present in only individual tumour cells (<10%). The intensity of immunohistochemical reactions with MDR1/P-gp was appraised using the semi-quantitative immunoreactive score (IRS) scale [17], in which the score reflected both the intensity of the reaction and the proportion of positive cells (Table 2). The final score represented the product of points given for individual characteristics and ranged between 0 and 12. The intensity of immunohistochemical reactions was appraised independently by two pathologists; in doubtful cases, a re-evaluation was performed using a double-headed microscope.

Control reactions
In each case, control reactions were included, in which specific antibody was substituted by Primary Mouse Negative Control (DakoCytomation). Control reactions were also performed for each of the examined antigens. For MDR1/P-gp, positive controls involved sections of six formalin-fixed and paraffin-embedded human liver samples (from the archive of the Chair and Department of Histology and Embryology, University School of Medicine in Poznañ, Poland) for each antibody. To evaluate specificity of the COX-2 antibody (Cayman Chemical Company) we [18] and other investigators [8] performed blocking experiments using the COX-2 blocking peptide (Cayman Chemical Company) according to the manufacturer’s instructions.

Statistical analysis
Statistical analysis of the results took advantage of Statistica 98 PL software (Statsoft, Krakow, Poland). The employed tests included chi² test, Spearman’s rank correlation and ANOVA Kruskal-Wallis test. Kaplan-Meier’s statistics and log-rank tests were performed using SPSS software (release 10.0; SPSS Inc., Chicago, IL, USA) to estimate the significance of differences in survival times. The length of survival was defined as the time between the primary surgical treatment and diagnosis of a recurrent tumour or death due to the neoplastic disease. Because the univariate analysis failed to disclose any significant relationships between studied clinicopathological parameters (age, menopausal status, grade and stage) and overall survival and progression free time in studied patients (P > 0.05), no multivariate analysis was conducted. The absence of a relationship between the until now most recognised and most effective prognostic factors [19] and patient survival time resulted most probably from the highly uniform character of the examined group of patients. As many as 96% of the examined patients represented the stage II (UICC) [15]. The uniform character of the group allowed a more unequivocal evaluation of the effect of the intensity of expression of the studied protein on the survival time of the patients.

Results
Immunostaining in control preparations and in breast cancers
Immunostaining for COX-2 occurred in a cytoplasmic localization and was of varying intensity among individual cases (Fig. 3).
In six COX-2 positive cases, we performed blocking experiments using the COX-2 blocking peptide, as described previously [18]. We found no staining in control preparations (Fig. 1). Expression of COX-2 was noted in 46 cases (44%). Immunostaining for MDR1/P-gp occurred in membranes in samples of healthy human liver and in the cytoplasm and membranes in breast cancers, and was of varying intensity among individual cases (Fig. 2a,b). The mean overall immunoreactivity score for MDR1/P-gp expression detected with antibody C219 was 3.45 ± 3.49 standard deviation (range: 0 IRS to 12 IRS) and with antibody JSB-1 was 3.34 ± 3.49 standard deviation (range: 0 IRS to 12 IRS). We found a strict positive correlation between expression with C219 and JSB-1 (Spearman’s rank correlation, R = 0.99, P < 0.001).

Using the ANOVA rank Kruskal-Wallis test, we examined the relationship between COX-2 expression and the overall immunoreactivity score of MDR1/P-gp expression. We found that the overall immunoreactivity score of MDR1/P-gp expression with C219 and JSB-1 was significantly higher in cases showing expression of COX-2 (P < 0.0001) (Fig. 3a,b; Table 3).

Chi² tests were also used to analyse the relationships between the intensity of COX-2 and MDR1/P-gp expression on the one hand and the grade, stage, pT (UICC) [15], pN (UICC) [15] and menopausal status of studied patients on the other. We found that at a grade of G3, a significantly higher proportion of cases manifested COX-2 expression compared to patients with a G2 grade (Table 4). The pN1 cases were also shown to exhibit a higher overall immunoreactivity score for C219 and JSB-1 compared to pN0 cases (Table 4); similarly, cases with a G3 grade showed a higher overall immunoreactivity score for C219 and JSB-1 compared to those with a G2 grade (Table 4).

COX-2 and MDR1/P-gp expression and patient survival
Kaplan-Meier statistics were used to analyse overall survival time and progression-free survival. In the entire study group, the COX-2 positive cases manifested a significantly shorter overall survival time and progression-free survival compared to COX-2 negative cases (Fig. 4c,f). Cases with an overall C219 and JSB-1 immunoreactivity score between 0 and 3 were also shown to manifest a significantly extended overall survival time and progression-free survival compared to cases with an overall C219 and JSB-1 immunoreactivity score between 4 and 12 (Fig. 4a,b,d,e). The same results were obtained in the subgroup of patients that, following surgery, were treated only with chemotherapy (Fig. 5a–f).

Discussion
We have described the expression of COX-2 and MDR1/P-gp proteins detected by immunohistochemistry in primary invasive breast cancers. Following the recommendations of the St Judge MDR Workshop on ‘Methods to Detect MDR1/P-gp-associated Multidrug Resistance’ [20], we have used two different monoclonal antibodies (C219 and JSB-1) directed against MDR1/P-gp. We found a strict positive correlation between MDR1/P-gp expression detected with C219 and JSB-1. We have confirmed that the studied proteins are...
expressed in a subset of breast cancers [11,21-23]. No relationship was discovered between COX-2 expression and such clinicopathological traits as pT, pN, stage or menopausal status. A higher proportion of COX-2 positive cases was noted in G3 compared to G2 patients. Previously, we noted that COX-2 expression was significantly associated with higher grade, lymph node status and larger tumour size [11]. Ristimäki et al. [21] described COX-2 expression using a tissue microarray in 1,576 cases of invasive breast cancer. They demonstrated that elevated COX-2 expression was associated with a large tumour size and high histological grade. In the present study, we have corroborated the positive correlation between COX-2 expression and the unfavourable clinicopathological prognostic indices in another group of patients. We have shown that a higher overall MDR1/P-gp immunoreactivity score is associated with lymph node involvement and a higher histological grade. Numerous authors have demonstrated a positive correlation between MDR1/P-gp expression and tumour stage [24,25]. To our knowledge, this study demonstrates for the first time a significant positive correlation between overall MDR1/P-gp immunoreactivity score and grade of breast cancer tumours. Thus, expression of MDR1/P-gp is typical for the less differentiated cases of breast cancer.

Expression of COX-2 in tumour cells represents an unfavourable prognostic factor in numerous tumours [9,10]. We [11] and other authors [21] have previously demonstrated that COX-2 represents an independent unfavourable prognostic factor in breast cancers. In this study, we have shown that COX-2 positive cases exhibit a significantly shorter overall survival and progression-free time in the entire study group and in a group of patients treated postoperatively with cytostatic drugs. Thus, we have confirmed the previously described observations that COX-2 expression in breast cancer is a negative prognostic factor.

The unfavourable prognostic significance of MDR1/P-gp expression has been documented in several tumours, including breast cancer [24,26-29]. Most of the studies have described the negative prognostic significance in breast cancer cases treated with chemotherapy. Few of the studies have suggested that MDR1/P-gp may also participate in the resistance to hormonal therapy [28]. In our study, we have

| Characteristics | COX-2 positive | COX-2 negative | P value | Chi² test | C219 high (IRS 4–12) | C219 low (IRS 0–3) | P value | Chi² test | JSB-1 high (IRS 4–12) | JSB-1 low (IRS 0–3) | P value | Chi² test |
|----------------|----------------|----------------|---------|-----------|---------------------|---------------------|---------|-----------|---------------------|---------------------|---------|-----------|
| pT             |                |                |         |           |                     |                     |         |           |                     |                     |         |           |
| 1              | 8 (8)          | 9 (9)          |         |           | 7 (7)               | 10 (10)             |         |           | 8 (8)               | 9 (9)               |         |           |
| 2              | 37 (36)        | 49 (47)        |         |           | 35 (34)             | 51 (49)             |         |           | 36 (35)             | 50 (48)             |         |           |
| 4              | 1 (1)          | 0 (0)          | 0.4954  |           | 1 (1)               | 0 (0)               | 0.7869  |           | 1 (1)               | 0 (0)               | 0.6306  |           |
| pN             |                |                |         |           |                     |                     |         |           |                     |                     |         |           |
| 0              | 10 (10)        | 19 (18)        |         |           | 11 (11)             | 18 (17)             |         |           | 11 (11)             | 18 (17)             |         |           |
| 1              | 36 (35)        | 39 (37)        | 0.2117  |           | 32 (31)             | 43 (41)             | <0.001  |           | 34 (33)             | 41 (39)             | <0.001  |           |
| Stage          |                |                |         |           |                     |                     |         |           |                     |                     |         |           |
| I              | 1 (1)          | 2 (2)          |         |           | 1 (1)               | 2 (2)               |         |           | 1 (1)               | 2 (2)               |         |           |
| IIa            | 16 (15)        | 24 (23)        |         |           | 16 (15)             | 24 (23)             |         |           | 17 (16)             | 23 (22)             |         |           |
| IIb            | 28 (27)        | 32 (31)        |         |           | 25 (24)             | 35 (34)             |         |           | 29 (28)             | 31 (30)             |         |           |
| IIlb           | 1 (1)          | 0 (0)          | 0.6628  |           | 1 (1)               | 0 (0)               | 0.5915  |           | 1 (1)               | 0 (0)               | 0.5874  |           |
| Grade          |                |                |         |           |                     |                     |         |           |                     |                     |         |           |
| 2              | 26 (25)        | 45 (43)        |         |           | 25 (24)             | 46 (44)             |         |           | 26 (25)             | 45 (43)             |         |           |
| 3              | 20 (19)        | 13 (13)        | 0.0135  |           | 18 (17)             | 15 (14)             | <0.001  |           | 19 (18)             | 14 (13)             | <0.001  |           |
| Menopause      |                |                |         |           |                     |                     |         |           |                     |                     |         |           |
| Praemenopausal | 12 (12)        | 18 (17)        |         |           | 13 (13)             | 17 (16)             |         |           | 14 (13)             | 16 (15)             |         |           |
| Postmenopausal | 34 (33)        | 40 (38)        | 0.4553  |           | 30 (30)             | 44 (42)             | 0.8307  |           | 31 (30)             | 43 (41)             | 0.9703  |           |

COX-2, cyclooxygenase-2; MDR1/P-gp, MDR1/P-glycoprotein; IRS, immunoreactive score.
shown, both in the entire group of patients (in whom surgery was followed by hormonal therapy and/or radiotherapy) and in the group of patients postoperatively treated with chemotherapy, that patients with a higher overall MDR1/P-gp immunoreactivity score exhibited a significantly shorter overall survival and progression-free time. As shown by our data, expression of MDR1/P-gp may not only be linked to resistance to cytostatic drugs but, considering that the higher overall MDR1/P-gp immunoreactivity score is associated with lymph node involvement and higher histological grade, may also represent an unfavourable prognostic factor independent of the applied therapy.

Several reports have suggested that elevated expression of COX-2 may stimulate expression of MDR1/P-gp. Such a phenomenon has been demonstrated, for example, in mesangial cells of rat kidneys, in which transfection with the COX-2 gene was followed by an increase in MDR1/P-gp expression [14], and in cells of the gastric mucosa during infection with Helicobacter pylori [30]. Ratnasinghe et al. [31] have described a positive correlation between COX-2 and MDR1/P-gp expression in breast cancer cases and cell lines. In this study, we confirm that a higher overall MDR1/P-gp immunoreactivity score is typical for COX-2 positive breast cancer cases. To our knowledge, this study demonstrates for the first time a negative prognostic significance of COX-2 and MDR1/P-gp coexpression in breast cancers. The data suggest that clinical studies should be performed on coxibs in chemotherapy-supporting treatment. Apart from their anti-tumour effects, these drugs might prevent the development of, or decrease the intensity of, the already existing MDR phenomenon.

**Conclusion**

We have shown the predictive significance of the immunohistochemical estimation of COX-2 and MDR1/P-gp expression in human breast cancers. We found a positive correlation...
Kaplan-Meier analysis of 28 breast cancer patients treated postoperatively with chemotherapy. (a) Patients with a lower overall immunoreactivity score for MDR1/P-glycoprotein (MDR1/P-gp) expression detected with antibody C219 exhibit significantly longer overall survival. (b) Patients with a lower overall immunoreactivity score for MDR1/P-gp expression detected with antibody JSB-1 exhibit significantly longer overall survival. (c) Cyclooxygenase-2 (COX-2) negative cases exhibit significantly longer overall survival. (d) Patients with lower overall immunoreactivity score for MDR1/P-gp expression detected with antibody C219 exhibit significantly longer progression-free survival. (e) Patients with lower overall immunoreactivity score for MDR1/P-gp expression detected with antibody JSB-1 exhibit significantly longer progression-free survival. (f) COX-2 negative cases exhibit significantly longer progression-free survival.

between COX-2 and MDR1/P-gp expression and demonstrated that COX-2 and MDR1/P-gp are unfavourable prognostic factors in breast cancers and unfavourable predictive factors in chemotherapy-treated breast cancer cases. Clinical studies should be performed on coxibs as a supporting treatment in breast cancer chemotherapy.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
PS contributed to the conception and design of the study, performed immunohistochemistry experiments, statistics and interpretation of data. VM contributed to the conception and design of the study, statistics and interpretation of data. RM performed clinical data analysis and interpretation of data. KS, AW and MP performed immunohistochemistry experiments and contributed to statistical analysis and interpretation of data. JK was involved in clinical data analysis and interpretation of data. MD, CD, HL and MZ contributed to the conception and design of the study and interpretation of data. All the authors read and approved the final manuscript.

Acknowledgements
The study was supported by the Berliner Krebsgesellschaft e.V., Germany.

References
1. Jemal A, Thomas A, Murray T, Thun M: Cancer statistics. CA Cancer J Clin 2002, 52:23-47.
2. Mori I, Yang Q, Kakudo K: Predictive and prognostic markers for invasive breast cancer. Pathol Int 2002, 52:188-194.
3. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ Jnr, Dreshler A, Fulton S, Hendricks CB, Kemeny M, Kornblith AB, Louis TA, Markman M, Mayer R, Roter D: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for
breast cancer. November 1-3, 2000. J Natl Canc Inst 2001, 93(13):979-80.

4. Goldhirsch A, Glick JH, Gelber RD: Meeting highlights: interna-
tional consensus panel on the treatment of primary breast cancer. J Natl Canc Inst 1998; 90:1601-1608.

5. Lage H: ABC-transporters: implications on drug resistance from microorganisms to human cancer. Int J Antimicrob Agents 2003, 22:188-190.

6. Lage H: Drug resistance in breast cancer. Cancer Therapy 2003, 1:81-91.

7. Gasparini G, Longo R, Sarmiento R, Monabitò A: Inhibitors of cyclooxygenase-2: a new class of anticancer agents? Lancet Oncol 2003, 4:605-615.

8. Ristimäki A, Nieminen O, Saukonen K, Hotakainen K, Nordling S, Haglund C: Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol 2001, 158:849-853.

9. Denkert C, Kobel M, Reles A, Sehouli J, Dietel M, Hauptmann S: Expression of cyclooxygenase-2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002, 160:893-903.

10. Denkert C, Kobel M, Berger S, Kobel M, Siegert A, Hauptmann S: Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001, 61:303-308.

11. Denkert C, Winzer KJ, Muller BM, Weichert W, Pest S, Kobel M, Kristiansen G, Reles A, Siegert A, Gaski H, Hauptmann S: Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer 2003, 97:2978-2987.

12. Brueggemeier RW, Richards JA, Petrel TA: Aromatase and cyclooxygenase in breast cancer. J Steroid Biochem Mol Biol 2003, 86:501-507.

13. Davies G, Martin LA, Sacks N, Dowsett M: Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer chemoprevention. Ann Oncol 2002, 13:669-678.

14. Patel VA, Dunn MJ, Sorokin A: Regulation of MDR1 (P-glycoprotein) by cyclooxygenase-2. J Biol Chem 2002, 277:38915-38920.

15. Sobin LH, Wittekind C: TNM classification of malignant tumours. 6th edition. New York: Wiley-Liss Inc; 2002.

16. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991, 19:403-410.

17. Remmele W, Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Patholologie 1987, 8:138-140.

18. Denkert C, Weichert W, Pest S, Koch I, Licht D, Kobel M, Reles A, Sehouli J, Dietel M, Hauptmann S: Overexpression of the embryonic-lethal abnormal vision-like protein HuR in ovarian carcinoma is a prognostic factor and is associated with increased cyclooxygenase 2 expression. Cancer Res 2004, 64:189-195.

19. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Alred DC, Clark GM, Ruby SG, O’Malley F, Simpson JP, Connolly JL, et al.: Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.

20. Becker WT, Grogan TM, Willman CL, Cordon-Cardo C, Parham DM, Reis-Filho J, Andreff M, Bates SE, Berard CW, Boyett JM, et al.: Methods to detect P-glycoprotein-associated multidrug resistance in patients’ tumours: consensus recommendations. Cancer Res 1996, 56:3010-3020.

21. Ristimäki A, Sirviva A, Lundin J, Lundin M, Salminen T, Haglund C, Joesuhi H, Isola J: Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002, 62:632-635.

22. Kanzaki A, Toi M, Nakayama K, Bando H, Mutoh M, Uchida T, Fukushima M, Takebayashi Y: Expression of multidrug resistance-related transporters in human breast carcinoma. Jpn J Cancer Res 2001, 92:452-458.

23. Hennquin E, Delvincourt C, Pourn C, Jardillier JC: Expression of mdr1 gene in human breast primary tumours and metastases. Breast Cancer Res Treat 1993, 26:267-274.

24. Brocker DA, Morris LW, Levine AJ, Pettinga JE, Grudzien JL, Farkas DH: Immunohistochemical analysis of P-glycoprotein expres-
sion in breast cancer: clinical correlations. Ann Clin Lab Sci 1995, 25:52-59.

25. Sun SS, Hsieh JF, Tsai SC, Ho YJ, Lee JK, Kao CH: Expression of mediated P-glycoprotein multidrug resistance related to Tc-99m MIBI scintimammography results. Cancer Lett 2000, 153:95-100.

26. Gottesman MM, Fojo T, Bates SE: Multidrug resistance in can-
cer: role of ATP-dependent transporters. Nat Rev Cancer 2002, 2:48-58.

27. Materna V, Pleger J, Hoffmann U, Lage H: RNA expression of MDR1/P-glycoprotein, DNA-topoisomerase, and MRFP2 in ovarian carcinoma patients: correlation with chemotherapeut-
ic response. Gynecol Oncol 2004, 94:152-160.

28. Linn SC, Giaccone G, van Diest PJ, Blokhuis WM, van der Valk P, van Kalken CK, Kuiper CM, Pinedo HM, Baak JP: Prognostic rele-
van ce of P-glycoprotein expression in breast cancer. Ann Oncol 1996, 8:679-685.

29. Nooter K, Brutel DLR, Look MP, van Wingerden KE, Henzen-Log-
mans SC, Scheper RJ, Flens MJ, Klijn JG, Stoter G, Foekens JA: The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br J Cancer 1997, 76:486-493.

30. Nardone G, Rocco A, Vaira D, Staibano S, Budillon A, Tantagelo F, Sculli MG, Perna F, Salvatore G, Di Benedetto M, et al.: Expression of COX-2, mPGE-synthase 1, MDR-1 (P-gp), and Bcl-x1: a molecular pathway of H pylori-related gastric carcinogenesis. J Pathol 2004, 202:305-312.

31. Ratnasinghe D, Daschener PJ, Arner MR, Kaspzak BH, Taylor PR, Yeh GC, Tangara JA: Cyclooxygenase-2, P-glycoprotein-170 and drug resistance; is chemoprevention against multidrug resistance possible? Anticancer Res 2001, 21:2141-2147.